Skip to main content Accessibility help
×
Home
Hostname: page-component-559fc8cf4f-s65px Total loading time: 0.713 Render date: 2021-02-27T15:14:03.529Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Article contents

Beneficial Effects of Memantine in Every Day Medical Practice: Results from a Large Greek Observational Study

Published online by Cambridge University Press:  16 April 2020

S. Stamouli
Affiliation:
Department of Psychiatry, Eginition University Hospital, Athens, Greece
M. Tzanakaki
Affiliation:
Center for Mental Health, General Hospital of Chania, Chania, Greece
N. Laggis
Affiliation:
Department of Neurology, ‘Elpis’ General Hospital, Athens, Greece
S. Giatas
Affiliation:
Department of Neurology, 251 Military Hospital, Athens, Greece
G. Georgiadis
Affiliation:
Department of Neurology, Ippokrateion Hospital of Thessaloniki, Thessaloníki, Greece
M. Sestrini
Affiliation:
Department of Psychiatry, Sismanogleion Hospital of Athens, Athens, Greece

Abstract

Memantine, NMDA-R antagonist, is approved for the treatment of moderate-to-severe Alzheimer's disease (MMSE< 20) (AD). The purpose of this study was to evaluate the efficacy and safety of memantine when used in routine clinical practice.

The 6-months, observational, open-label, multicentre study in 202 specialist centers in Greece evaluated the efficacy of memantine using the MMSE and Instrumental Activities of Daily Living (IADL) scale at baseline, 3 and 6 months. Safety was evaluated by spontaneously reported adverse events (AEs). Statistical efficacy analyses were performed in the Intent-To-Treat (ITT) (at least one post-baseline evaluation) and Per Protocol (PP) datasets (evaluations at both 3 and 6 months).

The study included 2570 AD patients (age: 74.8±6.8, 54.6% women, baseline MMSE score: 18.0±5.0). 34.2% had received previous treatment with acetylocholinesterase inhibitors (AChEIs), while for 65.8% memantine was the first treatment option. At baseline 91.5% were prescribed memantine as monotherapy, the remainder also received AChEIs. During the 6 months of the study, 80.9% continued memantine monotherapy. MMSE score was significantly improved from baseline at 3 (17.9±5.1 vs 19.2±5.0, p< 0.001, repeated measures analysis of variance Hotelling's test, ITT) and 6 months (17.9±5.1 vs 19.7±5.1). At 6 months, 67% of the ITT population had improved their MMSE score and 18.6% had no change. 19 patients (0.7%) terminated the therapy prematurely due to AEs. AEs were reported in 182 (7.1%) patients: the most common was dizziness (1.45%). 8 (0.3%) of the AEs were severe.

These results in naturalistic settings support the excellent efficacy and tolerability profile of memantine.

Type
P01-93
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 0
Total number of PDF views: 2 *
View data table for this chart

* Views captured on Cambridge Core between 16th April 2020 - 27th February 2021. This data will be updated every 24 hours.

Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Beneficial Effects of Memantine in Every Day Medical Practice: Results from a Large Greek Observational Study
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Beneficial Effects of Memantine in Every Day Medical Practice: Results from a Large Greek Observational Study
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Beneficial Effects of Memantine in Every Day Medical Practice: Results from a Large Greek Observational Study
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *